New York, New York–(Newsfile Corp. – January 11, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of BioAge Labs, Inc. stock. (NASDAQ: BIOA) pursuant to and/or traceable to BioAge’s initial public offering conducted on September 26, 2024 (“IPO”). A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than March 10, 2025.
SO WHAT: If you purchased BioAge stock, you may be entitled to compensation without paying any fees or out-of-pocket expenses through a contingency fee agreement.
WHAT TO DO NEXT: To join the BioAge class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=33167 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than March 10, 2025. The lead plaintiff is the representative party that acts on behalf of the other class members in the conduct of the litigation.
WHY ROSEN’S LAW: We encourage investors to choose a qualified advisor with experience in successful leadership roles. Often the companies issuing the notices do not have comparable experience, resources or any significant recognition from their peers. Be wise in choosing an advisor. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and equity derivative litigation. The Rosen Law Firm secured the largest securities class action settlement to date against a Chinese company at the time. The Rosen Law Firm is ranked #1 by ISS Securities Class Action (WA:) Services for numerous securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named a Law360 Claimant Bar Association Titan. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the defendants touted its lead product candidate azelaprag in connection with BioAge’s ongoing STRIDES clinical trial with expectations of heat results in 2025. The defendants also mentioned its collaboration with Eli Lilly and Company (NYSE:) (“Lilly”) Chorus a clinical development organization that would advise and assist in all aspects of the design and implementation of the STRIDES trial. The defendants further discussed the potential of a phase II clinical trial combining azelaprag and semaglutide for the treatment of obesity in individuals 18 years of age and older. Therefore, the IPO disclosed to the public that there were no safety concerns and that BioAge expected superior results and met its primary endpoints for its STRIDES clinical trial.
Contrary to these claims, BioAge halted the ongoing STRIDES Phase 2 study of its drug candidate azelaprag after several subjects showed elevated liver enzyme levels warning of potential organ damage. As a result, the defendants terminated the clinical trial and halted further enrollment. Given the fact that Defendants failed to detect the possibility of hepatic transaminitis in any of their prior Phase 1 clinical trials and various preclinical toxicosis studies, Defendants’ statements in BioAge’s registration statement were false and/or materially misleading at the time of the IPO. When the true details came to market, the lawsuit alleges, investors suffered damages.
To join the BioAge class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=33167 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.
No class is certified. Until the class is certified, you will not be represented by an attorney unless you retain one. You can choose a lawyer of your choice. You can also remain an absent member of the class and do nothing at this time. An investor’s ability to participate in a potential future recovery does not depend on whether it is the lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm/.
Advertising of lawyers. Previous results do not guarantee a similar outcome.
——————————–
Contact information:
To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236847
